Radicava
NDC Package 70510-2172-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Radicava is edaravone is used to treat a certain type of nerve disease called amyotrophic lateral sclerosis (ALS, also commonly called Lou Gehrig's disease). Marketed by Mitsubishi Tanabe Pharma America, Inc., this product is identified by NDC 70510-2172 and is authorized under FDA application NDA209176.

Identification & Billing

NDC Package Code
70510-2172-1
Package Description
2 BAG in 1 CARTON / 100 mL in 1 BAG (70510-2172-0)
Product Code
70510-2172
11-Digit Billing Format
70510217201

Clinical Specifications

Proprietary Name
Radicava
Dosage Form
-
Usage Information
Edaravone is used to treat a certain type of nerve disease called amyotrophic lateral sclerosis (ALS, also commonly called Lou Gehrig's disease). It helps to slow down the worsening of this disease. However, it is not a cure for ALS, and it does not reverse nerve damage or muscle weakness.

Regulatory & Marketing

Labeler Name
Mitsubishi Tanabe Pharma America, Inc.
FDA Application #
NDA209176
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
05-05-2025
End Marketing Date
04-09-2021
Listing Expiration
04-09-2021
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70510-2172-1 identifies a specific commercial package of 2 bag in 1 carton / 100 ml in 1 bag (70510-2172-0) of Radicava, labeled by Mitsubishi Tanabe Pharma America, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Mitsubishi Tanabe Pharma America, Inc. on May 05, 2025. The current certification is valid through April 09, 2021.

What are the primary indications for this medication?

Edaravone is used to treat a certain type of nerve disease called amyotrophic lateral sclerosis (ALS, also commonly called Lou Gehrig's disease). It helps to slow down the worsening of this disease. However, it is not a cure for ALS, and it does not reverse nerve damage or muscle weakness.

How is this Mitsubishi Tanabe Pharma America, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70510217201. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70510-2172-1
11-Digit CMS (5-4-2)
70510-2172-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.